Best Puerto Rico Grants for Nonprofits

The NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) promotes innovative clinical trials on natural products, such as botanicals and dietary supplements. This funding opportunity supports studies that demonstrate significant scientific rationale and preliminary evidence for efficacy. Applications can explore various delivery methods and combinations with existing treatments to enhance outcomes. Funding is available for up to three years, aimed at bridging basic science discoveries into practical clinical applications.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award supports investigator-initiated clinical trials of natural products, including botanicals and dietary supplements. This funding opportunity aims to validate the pharmacokinetics and bioavailability of these products over three years in a phased approach. Successful trials will provide crucial data for further development and clinical application, emphasizing the importance of scientifically driven research in natural product efficacy.

The NIH Midcareer Investigator Award in Patient-Oriented Research (K24) supports mid-career health-professional doctorates by providing protected time for patient-oriented research (POR). This grant also enables recipients to serve as research mentors for clinical residents, fellows, and junior faculty. Key deadlines for applications span from June 2024 to February 2027, ensuring ample opportunities for interested applicants to engage in impactful research and mentoring.

The NIDDK is expanding its Gastroparesis Consortium into the Disorders of Gastrointestinal Interoception Consortium (DGIC) to explore various GI disorders linked to interoceptive processing. This initiative aims to include multiple Clinical Research Centers and a Scientific Data Research Center, focusing on multidisciplinary approaches to uncover mechanisms connecting GI function to symptoms. The effort seeks to identify biomarkers and novel therapeutic targets for future clinical trials, enhancing understanding and treatment of complex gastrointestinal conditions.

About BlackRock

We’re a global asset manager and technology provider dedicated to helping more and more people experience financial well-being. We help millions of people invest to build savings that serve them throughout their lives. The BlackRock Foundation which funds and partners with organizations that strengthen financial security for more people,

BlackRock Future Builders

BlackRock Future Builders is a $100 million philanthropic initiative funded by The BlackRock Foundation to expand economic opportunity and power the next generation of America’s skilled trades workers. Through this Request for Proposals (RFP) process, The Foundation seeks to support U.S. nonprofit organizations (i.e., registered 501(c)3 organizations) delivering or supporting high‑quality skilled trades training.

This competitive grant opportunity operates in parallel to other BlackRock Future Builders partnerships and is intended to surface additional, regionally grounded solutions across the skilled trades ecosystem. Organizations may propose direct worker training programs or capacity‑building efforts that enable systems to function more effectively and at greater scale. This first round RFP will be administered by Jobs for the Future (JFF), a national nonprofit that transforms U.S. education and workforce systems.

Focus Areas and Solutions

Applicants may propose worker training or capacity‑building solutions aligned to skilled trades workforce development.

• Worker training interventions may include direct service proposals such as pre-apprenticeship or career navigation programs, workforce training programs, apprenticeship programs, or wraparound participant supports that are supportive of training persistence and completion.
• Capacity-building interventions are organizational and system-focused, rather than in direct service of participants, and may include, but are not limited to, proposals such as ecosystem-building, demonstration projects, technology or tool adoptions, or research, among others.

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) aims to enhance understanding of inflammatory bowel diseases (IBD) through genomic research. By leveraging patient cohorts and advanced data science, the IBDGC seeks to identify genetic risk factors and develop predictive biomarkers for disease outcomes. This initiative will improve medical management and advance precision medicine for IBD patients, addressing the need for effective diagnostics and treatment strategies in this chronic condition.

The Center for Inherited Disease Research (CIDR) provides high-throughput sequencing and genotyping services to support genetic research. It aims to identify genes linked to health and disease and enhance specimen classification through advanced genomic data. CIDR is a vital NIH initiative, offering cutting-edge platforms and statistical support that cannot be replicated in individual labs. For more information on their services, visit their website.

The National Centers for Biomedical Imaging and Bioengineering (NCBIB) provide critical resources for biomedical imaging and bioengineering research. This funding opportunity supports the development of innovative technologies tailored to the needs of basic, translational, and clinical researchers. NCBIB facilitates technology access, training, and dissemination, enhancing collaboration and advancing the field. Applications are encouraged to foster advancements that address complex biomedical challenges.

The Integrated Viral Hepatitis Surveillance, Testing, Treatment, and Prevention Programs for Health Departments (IVH-STTP) aims to strengthen viral hepatitis surveillance and prevention efforts across the United States. By enhancing outbreak response capabilities and promoting testing and treatment in high-impact settings, this initiative seeks to improve public health outcomes. Key components include partnerships, strategic planning, and perinatal hepatitis C programs, ultimately striving for better access to prevention and treatment services, aligning with CDC priorities.

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Data Coordinating Center aims to enhance understanding of inflammatory bowel disease (IBD) by coordinating extensive genetic research. By leveraging diverse patient cohorts and advanced data science techniques, the center seeks to identify genetic risk factors, develop predictive biomarkers, and improve IBD patient management. This initiative will facilitate collaboration among various research centers and ensure efficient data collection and sharing to foster advancements in precision medicine for IBD.

The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC) aims to enhance understanding of gastrointestinal disorders by expanding the previous Gastroparesis Consortium's research scope. This initiative will include adult and pediatric conditions linked to impaired interoceptive processing, utilizing multidisciplinary approaches to uncover mechanisms connecting GI function to symptoms, identify biomarkers for treatment efficacy, and explore new therapeutic targets for future clinical trials.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

About

Paul Newman was born and raised in Ohio by parents who owned a successful sporting goods store. He enlisted in the Navy and completed his military service as a radioman/gunner in the Pacific during World War II. Seeing his father’s business ethic during the Great Depression and experiencing the war fueled his desire to help others in need.

In 1958, Paul made his acting debut on Broadway in “Picnic,” where he also met his future wife, Joanne Woodward. Paul started a successful race car driving career inspired by training for the film Winning. He went on to win second place in the 24 Hours of Le Mans, the world’s oldest endurance race event. After years of acting and being recognized for his achievements on screen and stage, he received many accolades including an Oscar for Best Actor in The Color of Money.

Paul used his fame for good. He was dedicated to civil rights–attending the March on Washington in August 1963–women’s rights, and gay rights. He used his platform to advocate for equal pay for his female co-stars. He was a vocal political advocate committed to ending the nuclear arms race and determined to elect opponents of war and militarism. President Jimmy Carter appointed him to a United Nations General Assembly session on nuclear disarmament.

In 1982, Paul Newman and his friend Hotch founded a food company on a bit of a lark. They turned a profit selling salad dressing that first year, and did something truly radical when they decided to “give it all away” to good causes.

Paul established Newman’s Own Foundation to ensure the continuation of his philanthropic legacy after his passing. 40+ years since its founding, his first of its kind food company and its innovative business model are still going strong.

Garden Grants

Through Whole Foods Market’s Garden Grant program, schools turn outdoor spaces into powerful hands-on learning gardens that connect kids with food, spark their curiosity and support classroom curriculum.

The DICE program, funded by the US DOD's Advanced Research Projects Agency, aims to develop decentralized AI coordination and control algorithms. This initiative focuses on creating a scalable and resilient network of AI agents capable of executing long-term missions in challenging environments while ensuring human oversight. By leveraging principles of self-organization, DICE seeks to enhance the adaptability and predictability of AI behavior, promoting robust outcomes akin to the internet's decentralized architecture.

The WaterSMART Cooperative Watershed Management Program offers funding to eligible entities for developing local solutions to water management issues. This initiative supports watershed group development, restoration planning, and project design, promoting stakeholder cooperation and improving water reliability. It aligns with key priorities from the Trump administration, addressing complex water challenges and enhancing federal grant oversight. By facilitating these efforts, the program aims to stretch limited water resources and foster collaborative solutions among diverse stakeholders.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is inviting applications for the Clinical Trial Cooperative Agreement Program. This funding opportunity supports investigator-initiated, interventional clinical trials at various phases. Initial funding will facilitate the preparation needed to start trials, with successful milestones leading to further support. NIAMS emphasizes hypothesis-driven trials that promise significant clinical impact within its research mission.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is launching a funding opportunity for Exploratory Clinical Trials Grants. This program aims to support innovative clinical trials that enhance the understanding and treatment of arthritis and other musculoskeletal and skin conditions. Research proposals should focus on early-stage trials, including first-in-human studies, dose-finding, and biomarker evaluation. The initiative encourages the translation of promising laboratory findings into effective clinical practices, ultimately improving patient outcomes.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The BRAIN Initiative seeks to develop innovative tools and approaches for neuroscience research, focusing on cell-specific and circuit-specific processes within the central nervous system. This initiative encourages projects that enhance our understanding of brain architecture and function through novel technologies for characterizing neural components and advancing methods for recording and modulating neural activity. Applications are invited to address significant challenges and promote transformative breakthroughs in neuroscience.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.

The Clinical Data, Safety and Statistical Centers (CDSSC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance clinical research through comprehensive support. This includes statistical analysis, protocol development, and oversight of safety monitoring in studies related to asthma, autoimmune diseases, and transplantation. By coordinating these efforts, the program seeks to facilitate impactful research outcomes and improve public health outcomes through informed data-driven decisions.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

The NIAID aims to enhance our understanding of the interplay between chronic and infectious diseases through innovative precision systems biology research. By utilizing advanced technologies such as multi-omics and artificial intelligence, the initiative focuses on uncovering critical pathways that connect infections to chronic health issues. This multidisciplinary approach leverages longitudinal patient data to inform and improve prevention and treatment strategies, ultimately seeking to provide insights into disease progression and host-pathogen interactions.

The Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance research on asthma and related allergic diseases. This initiative fosters multi-center, multidisciplinary research to explore disease mechanisms and treatment responses. By promoting clinical trials and observational studies, the AADCRC seeks to advance understanding and improve interventions for conditions such as asthma and food allergies, ultimately benefiting public health.